Recently we pointed at a Forbe’s interview with Eric Drexler, in anticipation of his pending new book Radical Abundance. The book has shipped, and Drexler’s tour schedule now includes a few stops on the coasts of the U.S: New York: May 6th Los Angeles: May 8th & 9th Seattle: May 9th Find exact times and [...]
Archive for the 'Future Medicine' Category
In anticipation of Eric Drexler’s new book, Forbes contributor Bruce Dorminey interviews him about the meaning of nanotechnology and its revolutionary prospects. Selected excerpt: … In what fields would APM cause the most pronounced economic disruption and the collapse of global supply chains to more local chains? The digital revolution had far-reaching effects on information [...]
Nanoparticles decorated to avoid immune system recognition were tested in mice and shown to survive longer and deliver more imaging dye and drug to tumor cells.
In this Forbes interview, contributor John Nosta introduces us to a teen worth watching: fifteen-year-old Jack Andraka, whose effort to design a nanotube-based sensor for pancreatic cancer detection was initially ignored. The interview taps into some aspects of how innovation occurs and the challenges of bringing new ideas to fruition – aspects which transcend age, [...]
Core-shell nanocapsules deliver a potent protein complex to the nucleus of cancer cells where it induces them to commit suicide, while the complex degrades harmlessly in the cytoplasm of normal cells.
In a 47-minute interview Christine Peterson discusses the future that science and technology is bringing over the next few decades, and how to get involved to push the future in a positive direction.
An interview with Foresight Co-Founder and Past President Christine Peterson covering both the current state and the future prospects of nanotechnology is available on Youtube.
A demonstration that most fundamental biological processes can be implemented in a test tube as efficiently as in live bacteria provides synthetic biology the tools to create a ‘new industrial revolution’, which may or may not lead to more general molecular manufacturing.
Optimizing the size and charge of nanoparticles engineered from polymers delivers drugs directly to mitochondria, effectively treating cells with drugs for a variety of diseases.
A combination of theoretical and experimental work on peptoids, synthetic analogs of proteins, points to the ability to design peptoids with desired structures and functions.
Studies in mice with otherwise fatal blood clots have shown that targeting a clot-busting drug to regions where blood flow is blocked restores circulation and increases survival with a much lower, safer dose of the drug.
Nanotechnology combines an enzyme and a DNA molecule on the surface of gold nanoparticles to destroy hepatitis C virus in human cells and in a mouse model of disease.
Nanoparticles made from specific DNA and RNA strands, homogeneous in size, composition, and surface chemistry, proved superior to other nanoparticles in silencing gene expression in tumors in mouse experiments.
A new nanomaterial provides a three million-fold improvement in the sensitivity of common medical tests, potentially permitting earlier detection of cancer and Alzheimer’s disease.
A variety of protein cage structures have been constructed by designing specific protein domains to self-assemble as atomically precise protein building blocks in defined geometries.
A set of 310 short single-stranded DNA tiles, plus a few additional short sequences for the edges, has been used to form more than a hundred large, complex DNA objects.
Nancy K Mize, PhD, Scientist, Innovator, and CEO of GENOGEN Inc., will continue Foresight’s local Bay Area community events with a lecture “GENOGEN: Regenerating Skin for Life”. GENOGEN is developing products that activate resident skin stem cells to stimulate local areas of regeneration of skin naturally – the way children heal.
Nanoparticles targeted to cancer cells by antibodies cannot achieve enough specificity to kill drug-resistant cancer cells while sparing normal cells, but can achieve enough specificity to produce nanobubbles only in cancer cells, so the drug only enters cancer cells.
Gold nanostars targeted to a protein over-expressed in most cancer cells are shuttled by that protein directly to the cancer cell nucleus where illumination with a laser light releases a drug that deforms the nucleus and kills the cell.
Clinical trials in patients with advanced or metastatic tumors using targeted nanoparticles to deliver a standard chemotherapeutic drug showed tumor shrinkage, even in the case of cancers for which that drug is not normally effective.